Disorders of a modern lifestyle: reconciling the epidemiology of inflammatory bowel diseases

University of Manitoba Inflammatory Bowel Disease Clinical and Research Centre, Winnipeg, Manitoba, Canada.
Gut (Impact Factor: 13.32). 06/2008; 57(9):1185-91. DOI: 10.1136/gut.2007.122143
Source: PubMed

ABSTRACT A lasting lesson for gastroenterologists was the failure of traditional epidemiologic approaches to raise the possibility of a transmissible agent as a cause of peptic ulcer disease. Another lesson was that the solution to some human disorders can never be found by reliance on research focused exclusively on the human host, without due reference to the interface with the microbial environment. In the case of inflammatory bowel diseases (IBD), excessive reliance on conventional risk factor epidemiology without adequate rapprochement with concepts of disease mechanisms is likely to provide more controversy, conflict and confusion than consensus. However, the changing epidemiology of IBD associated with societal transition from developing to developed status is of such consistency that it represents a model, and may facilitate reconciling disparate lifestyle and environmental factors with causal mechanisms.

  • Source
    Progr. in Nutr; 01/2014
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Contrary to most of studies concerning oat beta-glucan activity using non-purified oat milling fraction this study investigates aqueous extract of beta-glucan from oat (purity approx. 75%) with high (G1) and low (G2) molecular weight to verified its anti-inflammatory and antioxidant effects in a model of chronic LPS-induced enteritis. Chronic inflammatory bowel diseases, e.g. Crohn’s disease (CD) and ulcerative colitis (UC) are expanding with the highest annual CD incidence in North America and the highest annual UC occurrence in Europe. The study has been conducted on Spraque-Dowley rats fed diets supplemented with 1% of G1 or G2 beta-glucan. Obtained results revealed that supplementation with both beta-glucan fractions led to significant reduction of different type blood leucocytes (lymphocytes T and B, granulocytes and lymphocytes Tc). Higher reduction of lipid peroxidation was observed in healthy rats after G1 supplementation, while G2 led this reduction in enteritis groups, mainly due to the increase of antioxidative defense.
    Journal of Functional Foods 12/2014; DOI:10.1016/j.jff.2014.12.019 · 4.48 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: To identify the frequency of hair loss among patients with inflammatory bowel disease (IBD) and associated clinical and disease related factors. We performed a cross sectional study in a tertiary referral adult IBD clinic. Self-reported history and characteristics of hair loss as well as clinical and demographic information were collected. Data were analyzed using univariate and multivariate analyses. Two hundred and ten consecutive IBD patients were recruited; one hundred and fifty patients met predefined inclusion and exclusion criteria. Thirty-three percent of patients reported a history of hair loss. Age, gender, IBD type and disease duration were not associated with hair loss. Hair loss was reported less frequently among patients with use of mesalamine (54% vs 73%, P = 0.03) and anti-tumor necrosis factor medications (anti-TNF) (14% vs 40%, P = 0.001). In multivariate analyses adjusting for gender, IBD type and duration of disease, these associations with mesalamine and anti-TNF remained significant [(adjusted values for mesalamine (OR = 0.43, 95%CI: 0.19-0.86) and anti-TNFs (OR = 0.28, 95%CI: 0.08-0.98)]. Hair loss is common among patients with IBD. Mesalamine and anti-TNF medications were associated with lower odds of hair loss. Further studies are required to assess the mechanism of hair loss among patients with IBD.
    World Journal of Gastroenterology 01/2015; 21(1):229-32. DOI:10.3748/wjg.v21.i1.229 · 2.43 Impact Factor